CervoMed was testing neflamapimod in the 159-patient trial as a treatment for a form of dementia that is caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells.

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.

frontotemporal dementia, and ischemic stroke recovery. Receive News & Ratings for CervoMed Inc Daily - Enter your email ...

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a late-stage study. The drug in question is neflamapimod, a p38 MAP ...

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy ...

(RTTNews) - CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies or DLB failed to demonstrate ...

CervoMed's RewinD-LB Phase 2b trial for neflamapimod in dementia with Lewy bodies failed to meet primary and key secondary endpoints. The trial's topline analysis revealed suboptimal plasma drug ...

A midstage trial of a treatment for patients with dementia with Lewy bodies failed to meet its main goals CervoMed Inc.'s stock cratered early Tuesday after the biotech company said a midstage ...